Alvotech Initiates Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® | New

  • Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone diseases, with combined sales of nearly US$5.3 billion in 2021
  • AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studies

REYKJAVIK, Iceland, July 20. 10, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ:ALVO), a global biotechnology company focused on developing and manufacturing biosimilar medicines for patients worldwide, today announced the initiation of a pharmacokinetic study for AVT03. (denosumab), a candidate biosimilar to Prolia® and Xgeva®. The clinical study will evaluate the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects.

Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture. Xgeva® (denosumab), which is the same biologic in a different presentation, is indicated for the prevention of skeletal events such as pathologic fractures in adults with advanced malignancies involving bone. It is also indicated for the treatment of giant cell tumors of bone. In 2021, the combined worldwide net revenue from sales of Prolia® and Xgeva® was nearly US$5.3 billion1.

“The rapid progress in the development of our product portfolio illustrates the capabilities of Alvotech’s biosimilars platform. This milestone of the AVT03 program is another step in our important mission to improve lives by expanding access to affordable biologic medicines,” said Joseph McClellan, Chief Scientific Officer.

Alvotech’s current portfolio of eight products and product candidates targets the treatment of autoimmune diseases, ocular disorders, osteoporosis, respiratory diseases and cancer. Of these, four products have been launched or have entered clinical studies. Alvotech launched its first marketed product AVT02 (adalimumab), a biosimilar to Humira®, in Europe and Canada. In May, Alvotech announced positive initial results from a confirmatory, safety and efficacy clinical study and pharmacokinetic (PK) study for AVT04 (ustekinumab), a proposed biosimilar to Stelara®. In July, Alvotech announced the launch of a confirmatory clinical study for AVT06 (aflibercept), a proposed biosimilar to Eylea®.

1Based on manufacturer’s reported sales

About Alvotech

Alvotech specializes in the manufacture of biosimilars, to improve lives by expanding access to affordable biologic medicines. Founded by Robert Wessman, Alvotech seeks to be a global leader in biosimilars by providing high-quality, cost-effective biologics enabled by a vertically integrated approach from R&D to fill-and-finish manufacturing. To enable global reach, Alvotech has formed a network of strategic business partnerships in over 90 countries, in the United States, Canada, Europe, Asia, Latin America, Africa and the Middle East. Alvotech’s current portfolio of eight biosimilars and biosimilar candidates includes AVT02 (adalimumab), a Humira® biosimilar that is approved and marketed in Europe (Hukyndra®) and Canada (Simlandi®) and seven biosimilar candidates targeting immunology , oncology, respiratory disease, bone disease and ophthalmology. For more information, visit

About AVT03 (denosumab)

AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia® and Xgeva® (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, leading to a reduction in osteoclast number and function, thereby decreasing bone resorption and cancer-induced bone destruction. AVT03 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

About AVT02 (adalimumab)

AVT02 is a monoclonal antibody and a biosimilar to Humira® (adalimumab), which inhibits tumor necrosis factor (TNF). AVT02 is not approved outside the EU, Norway, Iceland, Lichtenstein, UK, Switzerland and Canada. AVT02 files are being examined in several countries; in the United States, the original BLA for approval as a biosimilar is in deferred status, pending finalization of the BLA application review.

About AVT04 (ustekinumab)

AVT04 is a monoclonal antibody and biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines called interleukin-12 and interleukin-23 that are involved in inflammatory and immune responses. Abnormal regulation of these cytokines has been linked to immune-mediated diseases, such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. AVT04 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

About AVT06 (aflibercept)

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept). Aflibercept binds to vascular endothelial growth factors (VEGF), inhibiting VEGF receptor binding and activation, neovascularization and vascular permeability. AVT06 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

Forward-looking statements

Certain statements contained in this communication may be considered “forward-looking statements”. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities, including the development of ongoing products, future plans and intentions, results, level of activities, performance, objectives or achievements or other future events, expected patient recruitment, potential approval and commercial launch of its product candidates and the timing the announcement of clinical study results, regulatory approvals and market launches, and the estimated size of the total addressable market for Alvotech’s pipeline products. In some cases, you can identify forward-looking statements by words such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negative terms of these terms or variations thereof or similar terminology. These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements are based on estimates and assumptions which, although believed to be reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Alvotech’s control. Alvotech. Factors that could cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against Alvotech or others as a result of the business combination between Alvotech Holdings SA, Oaktree Acquisition Corp. II and Alvotech, with Alvotech as the surviving company; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business and/or competitive factors; (5) Estimates of Alvotech’s expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize its pipeline product candidates; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to recruit and retain patients in clinical studies; (9) the ability of Alvotech or its partners to obtain regulatory approvals for planned clinical studies, study plans or sites; (10) The ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development schedules and plans; (11) Alvotech’s ability to obtain and maintain regulatory approval or clearances for its product candidates, including the timing or likelihood of expansion into additional markets or geographies; (12) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing agreements; (13) Alvotech’s ability, and that of its business partners, to execute their strategy to commercialize approved products; (14) Alvotech’s ability to manufacture a sufficient commercial supply of its approved products; (15) the outcome of pending and future litigation regarding Alvotech’s products and product candidates; (16) the potential impact of the ongoing COVID-19 pandemic on FDA review timelines, including its ability to conduct timely inspection of manufacturing sites; and (17) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” which Alvotech may from time to time file or provide to the SEC. There may be additional risks that Alvotech is not currently aware of or that Alvotech currently believes to be immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be taken as a representation by anyone that the forward-looking statements set forth herein will be realized or that any of the results contemplated by such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech undertakes no obligation to update these forward-looking statements or to notify the recipient of any matter of which either becomes aware that may affect any matter referred to in this communication. Alvotech disclaims all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted in this communication and such liability is expressly disclaimed. The recipient agrees not to seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisers or representatives liable in any respect for the provision of this communication, information contained in this communication, or the omission of any information from this communication.


Alvotech Investor Relations

[email protected]

Alvotech Corporate Communications

[email protected]


About Author

Comments are closed.